{"id":"60329985751-43","name":"Shire","registrationDate":"2011-04-28T18:17:56.779+01:00","category":2,"subCategory":3,"legal":"Limited company","web":"http://www.shire.com/shireplc/en/home","country":"Ireland","headAddress":"Riverwalk; Citywest Business Campus, 5","headCity":"Dublin","headPostCode":"24","headPhone":"(353)14 29 77 00","boss":"Flemming Ornskov","bossTitle":"Mr","bossPosition":"Chief Executive Officer","membersCount":6,"membersFTE":"2.25","membership":"Shire is a member of:&#xd;\n&#xd;\nEuropean Association of Bioindustries (EuropaBio)&#xd;\nEuropean Biopharmaceutical Enterprises (EBE)&#xd;\nEuropean Biosimilars Group (EBG)&#xd;\nEuropean Federation of Pharmaceutical Industries and Associations (EFPIA)&#xd;\nPlasma Protein Therapeutics Association (PPTA)&#xd;\n&#xd;\nAmerican Chamber of Commerce to the European Union (AmCham EU)&#xd;\nBritish Chamber of Commerce in Belgium&#xd;\nEuropean Policy Centre (EPC)&#xd;\nFriends of Europe","memberOrga":"","goal":"Shire is the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening.&#xd;<br />&#xd;<br />We are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.","acronym":"Shire","interests":"Competition, Consumer Affairs, Economic and Financial Affairs, Education, Employment and Social Affairs, Energy, Enterprise, Environment, General and Institutional Affairs, Information Society, Internal Market, Public Health, Research and Technology, Taxation, Trade, Youth","euInitiatives":"All initiatives, policies, and legislation related to the biopharmaceutical sector and patient access to innovative medicines. These include:&#xd;<br />&#xd;<br />European Commission's annual work programme&#xd;<br />European Medicines Agency&#xd;<br />Healthcare policies&#xd;<br />Health Technology Assessment&#xd;<br />Innovative Medicines Initiative&#xd;<br />Intellectual Property&#xd;<br />Patient access to innovative medicines&#xd;<br />Patient safety&#xd;<br />Personalised medicines&#xd;<br />Pharmaceutical legislation&#xd;<br />Pharmaceutical sector policies&#xd;<br />Rare disease policies&#xd;<br />Research &amp; Development","lastUp":"2017-04-21T11:57:33.398+01:00","customers":"","costAbsolu":"","costRange":"","turnoverAbsolu":0,"turnoverRange":""}